Fact-checked by Grok 2 weeks ago

Scleroderma

Scleroderma is a rare group of autoimmune diseases; the systemic form is also known as systemic sclerosis. It is characterized by excessive collagen production leading to the hardening and tightening of the skin and connective tissues, which can extend to blood vessels and internal organs such as the lungs, heart, kidneys, and digestive tract.^[1] It affects approximately 300,000 people in the United States,^[2] with an incidence peaking between ages 30 and 50, and is more common in women than in men.^[3] The condition arises from an overactive immune response that triggers inflammation and fibrosis, resulting in progressive tissue damage without a known cure, though treatments can manage symptoms and slow progression.^[4] Scleroderma is broadly classified into two main categories: localized and systemic. Localized scleroderma, which includes subtypes like morphea and linear scleroderma, primarily affects the skin and sometimes underlying tissues or muscles, often appearing as patches of thickened or discolored skin without widespread organ involvement; it is more prevalent in children.^[3] Systemic scleroderma, the more severe form, involves both the skin and internal organs and is subdivided into limited cutaneous systemic sclerosis (with gradual skin changes mainly on the face, hands, and forearms) and diffuse cutaneous systemic sclerosis (with rapid, widespread skin thickening beyond the elbows and knees, leading to greater organ risk).^[1] Common symptoms include Raynaud's phenomenon, where fingers and toes turn white or blue in response to cold or stress due to blood vessel spasms, affecting up to 95% of systemic cases; skin changes such as swelling, itching, and shiny tightening; and joint pain or stiffness.^[4] Organ-specific manifestations may involve digestive issues like heartburn, difficulty swallowing, or bloating from esophageal dysfunction; respiratory problems such as shortness of breath from lung fibrosis or pulmonary hypertension; and cardiovascular complications like irregular heartbeats or heart failure.^[3] Complications can be life-threatening, including interstitial lung disease (a leading cause of death), scleroderma renal crisis leading to kidney failure, and calcinosis (calcium deposits under the skin).^[1] The exact causes of scleroderma remain unknown, but it involves a combination of genetic predisposition, environmental triggers (such as exposure to silica dust or solvents), and immune system dysregulation that promotes abnormal collagen deposition.^[4] Risk factors include female sex (with women four to nine times more likely to develop it), African American ethnicity (associated with earlier onset and more severe lung and skin involvement), and family history, though the disease is not directly inherited.^[3] Early diagnosis through physical exams, blood tests for autoantibodies, and imaging is crucial for improving outcomes, as timely interventions like immunosuppressants can mitigate fibrosis and vascular damage.^[1]

Overview and Classification

Definition

Scleroderma is a chronic autoimmune connective tissue disorder characterized by excessive deposition of collagen in the skin and internal organs, resulting in progressive fibrosis and hardening of affected tissues.^[1]^[5] This pathological process primarily involves the dysregulation of fibroblasts, leading to an overproduction of extracellular matrix components that stiffen the connective tissues.^[6] The disease manifests through a characteristic triad of inflammation, vasculopathy, and fibrosis, which collectively contribute to tissue remodeling and dysfunction.^[7] The term "scleroderma," derived from the Greek words "skleros" (hard) and "derma" (skin), describes the focal skin hardening observed in early cases and is now used to refer to a group of disorders involving skin thickening, including both localized forms affecting primarily the skin and systemic sclerosis (SSc), the systemic form with multi-organ involvement.^[8]^[9] This distinction highlights scleroderma's evolution from a perceived dermatological condition to a recognized systemic autoimmune entity.^[10] Historically, scleroderma was first detailed in medical literature in 1753 by Italian physician Carlo Curzio, who described a case of rigid, wood-like skin in a young patient, though the term itself was coined in 1836 by Giovambattista Fantonetti to capture the skin's leathery induration.^[11] By the late 19th century, reports emerged linking skin changes to internal organ pathology, such as pulmonary and renal involvement, but it was not until the 20th century—particularly with Robert H. Goetz's 1945 introduction of "progressive systemic sclerosis"—that the disease's multisystem nature was formally acknowledged, shifting focus from isolated cutaneous fibrosis to widespread autoimmune-mediated damage.^[12] Scleroderma remains a rare disorder, with a global prevalence estimated at 38 to 341 cases per million individuals for systemic forms, underscoring its low incidence and the need for specialized diagnostic awareness.^[13]

Classification

Scleroderma is primarily classified into two major categories: localized scleroderma, which is confined to the skin and subcutaneous tissues without systemic involvement, and systemic sclerosis (SSc), a multisystem autoimmune disease characterized by widespread fibrosis affecting the skin and internal organs.^[5] Localized scleroderma includes subtypes such as morphea, presenting as circumscribed plaques of skin thickening, and linear scleroderma, which often follows a linear pattern along limbs or the face, potentially leading to musculoskeletal deformities if untreated.^[14] In contrast, SSc involves vascular abnormalities, immune dysregulation, and fibrosis extending beyond the skin.^[15] Within SSc, subtypes are delineated based on the extent and distribution of skin involvement. Limited cutaneous SSc (lcSSc), comprising about 60% of cases, features skin thickening distal to the elbows and knees, often accompanied by the CREST syndrome features—calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia—with a more indolent progression and later onset of organ complications.^[15] Diffuse cutaneous SSc (dcSSc), affecting around 30% of patients, involves proximal skin fibrosis extending beyond the limbs to the trunk, with rapid progression and early internal organ involvement such as interstitial lung disease.^[5] A rarer form, SSc sine scleroderma (less than 5% of cases), lacks clinically apparent skin changes but manifests systemic features including pulmonary fibrosis, cardiac involvement, and gastrointestinal dysmotility.^[16] Juvenile scleroderma represents a distinct category primarily affecting children under 16 years, with localized forms (such as linear scleroderma or morphea) being more common than systemic variants, though juvenile SSc can occur and follows similar adult subtyping but with unique pediatric presentations like growth impairment.^[17] Scleroderma overlap syndromes occur when features of SSc coexist with other connective tissue diseases, most notably mixed connective tissue disease (MCTD), which combines elements of SSc, systemic lupus erythematosus, and polymyositis, often driven by anti-U1 RNP antibodies and presenting with puffy fingers, arthritis, and milder skin fibrosis.^[18] Other overlaps include scleromyositis (SSc with inflammatory myopathy) and synthetase syndromes, highlighting the heterogeneous spectrum of autoimmune fibrosing disorders.^[19]

Clinical Presentation

Signs and Symptoms

Scleroderma, also known as systemic sclerosis (SSc), presents with a range of early clinical manifestations that primarily affect the skin, vasculature, musculoskeletal system, and gastrointestinal tract, often beginning subtly before progressing.^[5] These symptoms typically emerge in adults, with women affected four to eight times more frequently than men, and early recognition is crucial for timely intervention.^[5]^[20] Cutaneous signs are among the most prominent and often the initial indicators of the disease. In the early edematous phase, patients commonly experience puffy or swollen fingers and hands due to inflammation and fluid retention, accompanied by pruritus (itching) that can lead to excoriations.^[1] ^[5] As the condition advances to the fibrotic phase, skin tightening begins distally in the fingers and hands—a feature known as sclerodactyly—progressing proximally toward the arms, face, and trunk in diffuse forms, resulting in taut, shiny skin with reduced flexibility.^[5] Hyperpigmentation or hypopigmentation may occur, creating a characteristic salt-and-pepper appearance, while digital ulcerations frequently develop at sites of trauma, such as fingertips, due to underlying vascular compromise.^[21] ^[5] Vascular symptoms, particularly Raynaud's phenomenon, serve as the earliest and most common sign, affecting more than 95% of individuals with SSc and often preceding other manifestations by months to years.^[22] This vasospastic disorder causes episodic color changes in the fingers and toes—typically progressing from pallor (white) to cyanosis (blue) and then rubor (red)—triggered by exposure to cold or emotional stress, accompanied by pain, numbness, or tingling.^[5] ^[1] Musculoskeletal involvement contributes to discomfort and functional limitations from the outset. Patients frequently report joint pain (arthralgia) and stiffness, which may mimic inflammatory arthritis, alongside muscle aches (myalgia).^[5] Tendon friction rubs, palpable crepitus over tendons during movement, occur in up to 37% of early diffuse cases, particularly around the hands, wrists, ankles, and knees, indicating active inflammation.^[23] Sicca symptoms, such as dry mouth (xerostomia) and dry eyes (xerophthalmia), arise in a subset of patients due to secondary salivary and lacrimal gland involvement, exacerbating oral and ocular discomfort.^[24] Early gastrointestinal symptoms stem from dysmotility, affecting nearly 90% of patients and often manifesting as dysphagia (difficulty swallowing) and heartburn from esophageal involvement.^[5] These arise due to impaired peristalsis and lower esophageal sphincter function, leading to reflux and bloating shortly after disease onset.^[1] The disease timeline typically unfolds over an acute inflammatory phase lasting weeks to months, characterized by edema and vascular instability, transitioning to a chronic fibrotic phase over years, where skin and connective tissue hardening predominates.^[5] This progression varies by subtype, with limited cutaneous SSc showing slower evolution compared to diffuse forms.^[5]

Organ Involvement and Complications

Scleroderma, or systemic sclerosis (SSc), is characterized by progressive fibrosis and vascular abnormalities that lead to multisystem organ involvement, resulting in significant morbidity and mortality.^[5] Pulmonary, cardiac, renal, and gastrointestinal complications are among the most severe, often arising from fibrotic deposition and vasculopathy, with pulmonary issues accounting for approximately 60% of disease-related deaths combined.^[25] Pulmonary involvement manifests primarily as interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH), both of which contribute substantially to reduced survival. ILD, affecting up to 90% of patients with diffuse cutaneous SSc, presents with ground-glass opacities and reticular patterns on high-resolution computed tomography (HRCT), leading to progressive dyspnea and pulmonary fibrosis.^[26] PAH, occurring in 8-12% of SSc patients, involves vascular remodeling and right heart strain, with echocardiographic evidence of elevated pulmonary pressures and tricuspid regurgitation.^[20] Together, ILD and PAH are responsible for approximately 60% of SSc-related mortality, underscoring their role as leading causes of death.^[25] Cardiac complications arise from myocardial fibrosis, microvascular dysfunction, and pericardial involvement, occurring in 15-30% of patients and often remaining subclinical until advanced stages. Pericarditis, seen in up to 20% of cases, can lead to effusion or tamponade, while patchy myocardial fibrosis causes diastolic dysfunction and restrictive cardiomyopathy.^[27] Arrhythmias, including ventricular tachycardia, and conduction abnormalities such as bundle branch blocks are common, contributing to sudden cardiac events and heart failure, with cardiac causes accounting for about 26% of SSc deaths.^[25] Renal involvement most critically presents as scleroderma renal crisis (SRC), a life-threatening emergency affecting 10-25% of patients with diffuse cutaneous SSc, typically within the first 4-5 years of disease onset. SRC is characterized by malignant hypertension, thrombotic microangiopathy, and acute kidney injury, often requiring dialysis, with histological findings of intimal proliferation in renal arterioles.^[28] Although less common in limited SSc (1-2%), SRC carries a high mortality risk if untreated, emphasizing the need for vigilant blood pressure monitoring in at-risk patients.^[29] Gastrointestinal complications extend beyond initial dysmotility to advanced issues like intestinal pseudo-obstruction and malnutrition, impacting up to 90% of SSc patients over time. Chronic intestinal pseudo-obstruction results from smooth muscle atrophy and fibrosis, causing abdominal distension, nausea, and recurrent obstruction episodes.^[30] Small intestinal bacterial overgrowth, secondary to hypomotility, leads to malabsorption, diarrhea, and weight loss, exacerbating malnutrition and increasing hospitalization risks.^[31] Other notable complications include calcinosis, telangiectasias, and heightened malignancy risk. Calcinosis involves painful subcutaneous calcium deposits, most frequently in the fingers and elbows of limited SSc patients, leading to ulceration and infection.^[32] Telangiectasias, dilated superficial vessels forming mat-like patterns on the face and hands, occur in over 50% of cases and reflect underlying vascular fragility.^[5] SSc confers a 1.5- to 4-fold increased risk of malignancy, particularly lung cancer in those with ILD, due to chronic inflammation and fibrosis.^[33] Functional impacts from scleroderma further compound organ complications, with joint contractures limiting mobility and range of motion in up to 80% of patients, particularly in the hands and face. Digital ulcers, affecting about 50% of SSc patients, arise from vasculopathy and often become infected, leading to osteomyelitis or, in severe cases, amputations, thereby impairing daily activities and quality of life.^[34]

Etiology and Pathophysiology

Causes and Risk Factors

The exact cause of scleroderma remains unknown, but it is widely regarded as a multifactorial autoimmune disease arising from complex interactions between genetic predisposition, environmental exposures, and immunological dysregulation.^[5] No single causative agent has been identified, with evidence pointing to gene-environment interactions as key contributors to disease susceptibility.^[35] Genetic factors play a significant role in scleroderma risk, with certain human leukocyte antigen (HLA) alleles, such as HLA-DRB1*1104, conferring increased susceptibility, particularly in non-familial cases.^[36] Familial clustering occurs in approximately 1-2% of cases, indicating a heritable component, though the overall recurrence risk in first-degree relatives is low compared to the general population prevalence of about 0.026%.^[36] Epigenetic modifications, including alterations in DNA methylation patterns in immune cells and fibroblasts, have also been implicated in predisposing individuals to scleroderma by influencing gene expression related to fibrosis and autoimmunity.^[37] Environmental triggers are hypothesized to initiate or exacerbate the disease in genetically susceptible individuals, with occupational exposures to silica dust—common among miners and those in construction—showing the strongest associations, increasing risk by up to 3- to 25-fold in meta-analyses.^[38] Exposure to organic solvents, such as those encountered by cleaners or industrial workers (e.g., trichloroethylene and toluene), has similarly been linked to elevated risk, with odds ratios around 2-3.^[5] Viral infections, including cytomegalovirus (CMV) and parvovirus B19, are proposed as potential triggers through mechanisms like molecular mimicry, though direct causality remains unproven.^[39] Demographic factors further modulate risk, with scleroderma exhibiting a 4:1 female-to-male ratio, peaking in incidence between ages 30 and 50.^[1] Incidence is higher among African Americans, who often experience earlier onset and more severe manifestations, and particularly elevated in the Choctaw Native American population of Oklahoma, where prevalence reaches 66 per 100,000—over six times that in other Native American groups.^[40] Scleroderma also shows associations with other autoimmune rheumatic diseases, such as rheumatoid arthritis and systemic lupus erythematosus, suggesting shared predisposing factors.^[5]

Pathophysiological Mechanisms

Scleroderma, also known as systemic sclerosis (SSc), is characterized by a complex interplay of vascular injury, immune dysregulation, and fibrosis, forming the central triad of its pathogenesis. Vascular injury initiates the process, involving endothelial cell damage that leads to microvascular dysfunction, including apoptosis, intimal proliferation, and perivascular inflammation.^[5] This early vasculopathy manifests as reduced capillary density and chronic hypoxia, driven by an imbalance in vasoconstrictors like endothelin-1 (ET-1) and vasodilators such as nitric oxide.^[41] Immune dysregulation follows, with activation of T cells (particularly Th2 subsets) and B cells producing autoantibodies, such as anti-topoisomerase I, alongside cytokine release including IL-4, IL-6, IL-13, and TGF-β, perpetuating inflammation.^[42] Fibrosis ensues as the dominant feature, marked by excessive extracellular matrix (ECM) deposition from activated fibroblasts differentiating into myofibroblasts, which resist apoptosis and remodel tissues.^[43] Key signaling pathways underpin these processes. Transforming growth factor-β (TGF-β) is pivotal in fibrosis, signaling through Smad and non-Smad pathways to induce collagen synthesis, myofibroblast transdifferentiation (e.g., via endothelial-to-mesenchymal transition, EndoMT), and ECM accumulation.^[42] Platelet-derived growth factor (PDGF) promotes fibroblast proliferation and migration, with elevated levels in SSc lesions correlating to disease severity.^[41] Connective tissue growth factor (CTGF), often downstream of TGF-β, amplifies these effects by enhancing ECM production and vascular smooth muscle proliferation.^[43] Oxidative stress from reactive oxygen species (ROS) further exacerbates endothelial damage and fibrotic signaling, creating a vicious cycle.^[42] The disease progresses in distinct phases: an early inflammatory stage featuring a cytokine storm with IL-6 and IL-13 dominance, vascular insult, and immune activation, transitioning to a chronic fibroproliferative phase dominated by persistent myofibroblasts and ECM excess.^[5] The vascular-fibrosis link is critical, as hypoxia from vasculopathy upregulates ET-1 and angiogenesis inhibitors, promoting EndoMT and fibrogenic cytokine release that bridges endothelial injury to stromal remodeling.^[41] Animal models, such as bleomycin-induced dermal fibrosis in mice, recapitulate these mechanisms, demonstrating TGF-β-driven myofibroblast activation and the efficacy of targeting apoptosis pathways to reduce fibrosis.^[43]

Diagnosis

Diagnostic Approach

The diagnosis of scleroderma, also known as systemic sclerosis (SSc), begins with a thorough clinical evaluation, often prompted by hallmark symptoms such as Raynaud's phenomenon or skin thickening. The American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) 2013 classification criteria provide a standardized scoring system for confirming SSc, assigning points to features including skin thickening proximal to the metacarpophalangeal joints (9 points), puffy fingers (2 points), Raynaud's phenomenon (3 points), and sclerodactyly (4 points), among others such as fingertip lesions, telangiectasia, and abnormal nailfold capillaries. A total score of ≥9 indicates definite SSc, with a sensitivity of 91% and specificity of 92% in validation cohorts. To assess disease severity, the modified Rodnan skin score (mRSS) is commonly used, evaluating skin thickness via palpation in 17 body areas on a 0-3 scale per site, yielding a total range of 0-51; higher scores correlate with diffuse cutaneous involvement.^[44]^[45] Laboratory testing plays a central role in supporting the diagnosis and subtype classification. Antinuclear antibodies (ANA) are positive in over 90% of SSc patients, typically detected by immunofluorescence at a titer ≥1:80, serving as an initial screening tool. Specific autoantibodies further refine the diagnosis: anti-centromere antibodies (ACA) are associated with limited cutaneous SSc (prevalence ~50-70%), anti-topoisomerase I (anti-Scl-70) with diffuse cutaneous SSc (~20-40%), and anti-RNA polymerase III with rapid-onset diffuse disease and higher renal crisis risk (~20%). In active disease, inflammatory markers such as erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are often elevated, reflecting ongoing inflammation in approximately 25% of cases, particularly early in the course.^[46]^[47]^[48] Non-invasive imaging and specialized tests aid in evaluating organ involvement and microvascular changes integral to SSc diagnosis. Nailfold capillaroscopy, a bedside microscopy technique, reveals the characteristic "scleroderma pattern" in over 90% of patients, featuring giant capillaries (>50 μm), hemorrhages, avascular areas, and ramified/bushy loops, which precede clinical symptoms and support early classification. For pulmonary assessment, high-resolution computed tomography (HRCT) of the chest is the gold standard for detecting interstitial lung disease (ILD), present in 75-90% of SSc cases, showing patterns like ground-glass opacities or fibrosis. Transthoracic echocardiography screens for pulmonary arterial hypertension (PAH), estimating systolic pulmonary artery pressure via tricuspid regurgitant jet velocity, with guidelines recommending annual screening in at-risk patients due to PAH's prevalence of 8-15%.^[49]^[50]^[51] Skin biopsy is occasionally performed when clinical features are atypical, involving a 4-6 mm punch biopsy from affected areas to confirm fibrosis; histopathology demonstrates dense, homogenized collagen bundles in the dermis with reduced appendages, though it is rarely needed for systemic confirmation given the high specificity of clinical criteria. Early diagnosis is emphasized, ideally within 1-2 years of Raynaud's onset—the most common initial symptom in ~95% of cases—as this window allows intervention to mitigate progression to irreversible organ damage, per very early diagnosis of systemic sclerosis (VEDOSS) criteria.^[52]^[53]

Differential Diagnosis

The differential diagnosis of scleroderma, also known as systemic sclerosis, is essential because its skin thickening, Raynaud's phenomenon, and organ involvement can overlap with several other disorders, potentially leading to misdiagnosis if not carefully evaluated. Accurate differentiation relies on clinical history, physical examination, laboratory tests, and imaging to exclude mimics while confirming scleroderma-specific features such as autoantibodies and vascular changes.^[54] Rheumatologic conditions often mimic scleroderma through shared autoimmune mechanisms and inflammatory features. Systemic lupus erythematosus (SLE) can present with skin tightening and Raynaud's phenomenon, but is distinguished by characteristic malar rash, photosensitivity, and autoantibodies like anti-dsDNA, which are absent in scleroderma.^[55] Rheumatoid arthritis (RA) may imitate joint involvement and skin changes in scleroderma, yet typically features symmetric polyarthritis and positive rheumatoid factor (RF), without the prominent Raynaud's or digital ulcers seen in scleroderma.^[15] Mixed connective tissue disease (MCTD) overlaps with scleroderma in skin fibrosis and myositis-like symptoms, but is differentiated by high titers of anti-U1-RNP antibodies and less severe internal organ involvement compared to scleroderma.^[55] Dermatologic disorders can resemble the cutaneous manifestations of scleroderma, particularly localized skin induration. Eosinophilic fasciitis mimics limb skin thickening but involves deeper fascial layers, often with a characteristic "groove sign" on examination and peripheral eosinophilia, without Raynaud's phenomenon or visceral involvement.^[15] Morphea, a form of localized scleroderma, presents with patchy skin plaques but lacks the systemic and deeper tissue involvement of diffuse scleroderma, remaining confined to the dermis without vascular or organ complications.^[56] Lichen sclerosus primarily affects genital and perianal skin with white, atrophic patches and itching, differing from scleroderma's acral distribution and absence of epidermal atrophy or mucosal erosions.^[57] Vascular conditions may replicate the Raynaud's phenomenon prominent in scleroderma. Primary Raynaud's disease causes episodic vasospasm without underlying connective tissue disease, distinguished by normal nailfold capillaroscopy and absence of scleroderma-specific autoantibodies.^[56] Buerger's disease (thromboangiitis obliterans) can produce Raynaud-like symptoms and limb ischemia in young smokers, but involves medium-sized arteries and veins with superficial thrombophlebitis, lacking the microvascular changes and skin fibrosis of scleroderma.^[57] Other systemic disorders occasionally mimic scleroderma through fibrosis or infiltration. Amyloidosis leads to waxy skin thickening and organ dysfunction via amyloid deposition, differentiated by biopsy confirmation of amyloid and multiorgan infiltration without scleroderma autoantibodies.^[15] Graft-versus-host disease (GVHD), occurring post-hematopoietic stem cell transplant, can cause scleroderma-like skin sclerosis, but is identified by transplant history and gastrointestinal or hepatic involvement without Raynaud's.^[56] Nephrogenic systemic fibrosis (NSF) presents with diffuse skin induration following gadolinium-based contrast exposure in renal failure patients, distinguished by lack of Raynaud's, telangiectasias, and scleroderma-specific autoantibodies.^[54] Key differentiators across these mimics include the autoantibody profile, with scleroderma featuring specific antibodies like anti-centromere or anti-topoisomerase I, often absent in mimics; nailfold capillaroscopy showing a scleroderma pattern (giant capillaries, avascular areas) versus normal findings in primary Raynaud's or other non-scleroderma conditions; and the frequent absence of Raynaud's phenomenon in dermatologic or other mimics like eosinophilic fasciitis or NSF.^[58]^[59]

Management

Treatment Strategies

Treatment of scleroderma, also known as systemic sclerosis (SSc), focuses on disease-modifying pharmacological interventions to halt progression and manage organ-specific manifestations, as there is currently no cure.^[60] Immunosuppressive therapies target inflammatory and fibrotic processes, particularly in interstitial lung disease (ILD) and skin involvement, while vasculoprotective agents address vascular complications such as Raynaud's phenomenon and pulmonary arterial hypertension (PAH). Antifibrotic drugs and emerging biologics offer additional options for progressive fibrosis, and specific interventions are critical for scleroderma renal crisis (SRC). Treatment is tailored based on disease subtype, organ involvement, and severity, often guided by international recommendations.^[61] For ILD, a common and serious complication, mycophenolate mofetil (MMF) is recommended as first-line immunosuppression at doses of 2000–3000 mg daily, reducing the decline in forced vital capacity (FVC) compared to placebo.^[62] Cyclophosphamide serves as an alternative, particularly for more severe cases, with intravenous administration showing superiority over placebo in stabilizing lung function in randomized trials.^[63] Rituximab is suggested as an additional immunosuppressive option for SSc-ILD, particularly in refractory cases, based on evidence from clinical trials and guidelines showing FVC stabilization.^[60] Methotrexate is used for early diffuse cutaneous SSc to improve skin involvement, though its role in lung disease is less established.^[64] Tocilizumab, an interleukin-6 inhibitor, is recommended for SSc-ILD in patients with early diffuse cutaneous SSc, elevated inflammatory markers, or recent skin fibrosis progression, as phase 3 trials demonstrated stabilization of FVC decline.^[60]^[65] Antifibrotic therapy with nintedanib is indicated for progressive SSc-ILD, as demonstrated in the SENSCIS trial where it reduced the annual rate of FVC decline by approximately 44% compared to placebo over 52 weeks.^[66] Vasculoprotective treatments are essential for Raynaud's phenomenon, with dihydropyridine calcium channel blockers such as nifedipine as first-line therapy to reduce attack frequency and severity.^[67] For PAH, phosphodiesterase-5 (PDE-5) inhibitors like sildenafil improve exercise capacity and hemodynamics, often combined with endothelin receptor antagonists such as bosentan to enhance outcomes in SSc-associated PAH.^[68] In SRC, characterized by acute hypertension and renal failure, angiotensin-converting enzyme (ACE) inhibitors like captopril are the cornerstone of management, dramatically improving survival when initiated early to control blood pressure.^[69] Emerging interventions include autologous hematopoietic stem cell transplantation (HSCT) for severe early diffuse cutaneous SSc, which the ASTIS trial showed improved long-term event-free survival compared to cyclophosphamide, despite higher early treatment-related mortality.^[70]

Supportive Care

Supportive care in scleroderma plays a crucial role in managing symptoms, preventing complications, and enhancing quality of life through non-pharmacological and multidisciplinary strategies, particularly for patients with skin tightening, Raynaud's phenomenon, and organ involvement.^[71] These approaches complement pharmacological treatments by focusing on rehabilitation, symptom palliation, and lifestyle modifications to address the progressive nature of the disease.^[72] Physical and occupational therapy are essential components of supportive care to maintain joint mobility and function. Stretching exercises, performed regularly under guidance, help prevent contractures in the hands, face, and limbs by improving flexibility and reducing skin tightness.^[73]^[74] Occupational therapists often recommend splinting devices for hand function to counteract flexion deformities and support daily activities, such as grasping objects, thereby preserving independence.^[75]^[76] Wound care is vital for managing digital ulcers, a common complication arising from vascular issues in scleroderma. Moist dressings, such as hydrocolloid or occlusive types, promote healing by protecting the ulcer bed, maintaining a humid environment, and facilitating debridement of necrotic tissue.^[77]^[78] In cases of infection, antibiotics are used alongside these measures to control bacterial growth and prevent sepsis.^[79] For Raynaud's phenomenon, pneumatic gloves provide intermittent compression to improve circulation and reduce vasospasm in the digits.^[80] Nutritional support addresses gastrointestinal dysmotility, which affects up to 90% of scleroderma patients and can lead to malnutrition. Small, frequent, low-fat meals help manage esophageal reflux by easing digestion, while low-fiber/low-residue meals are recommended for intestinal pseudo-obstruction to promote motility and prevent obstruction.^[81]^[82] Proton pump inhibitors may be incorporated to control reflux symptoms, while severe cases require enteral feeding via tube to ensure adequate caloric intake and prevent weight loss.^[83]^[84] Pain management in scleroderma emphasizes a multimodal approach to alleviate musculoskeletal and neuropathic discomfort. Nonsteroidal anti-inflammatory drugs (NSAIDs) provide relief for joint pain and inflammation, while gabapentin targets neuropathic symptoms associated with nerve compression or vascular changes.^[85] Psychological support, including cognitive-behavioral therapy and support groups, aids in coping with chronic pain and the emotional burden of the disease.^[86]^[6] Multidisciplinary teams coordinate care to optimize outcomes, involving rheumatologists, pulmonologists, gastroenterologists, and therapists for holistic management.^[87] Patient education focuses on lifestyle adjustments, such as smoking cessation to improve vascular health and avoiding cold exposure to minimize Raynaud's attacks.^[4]^[88] Surgical interventions are reserved for refractory cases to address severe complications. Lung transplantation offers a life-saving option for patients with end-stage interstitial lung disease or pulmonary arterial hypertension, with outcomes comparable to other indications when extrapulmonary disease is stable.^[89]^[90] Sympathectomy, either chemical or surgical, can be performed for severe, unresponsive Raynaud's to interrupt sympathetic nerve activity and reduce digital ischemia.^[91]^[72]

Outcomes and Epidemiology

Prognosis

The prognosis of systemic sclerosis (SSc), the most severe form of scleroderma, varies widely depending on subtype and organ involvement, with overall 10-year survival rates ranging from 60% to 80%.^[25] Limited cutaneous SSc (lcSSc) generally carries a better outlook, with 10-year survival of 70% to 90%, compared to 50% to 70% for diffuse cutaneous SSc (dcSSc).^[92] These rates represent a marked improvement from the 1980s, when 10-year survival was approximately 40%, largely attributable to earlier detection and advances in supportive therapies.^[25] Several factors are associated with poorer prognosis in SSc patients. The diffuse subtype, involvement of interstitial lung disease (ILD), pulmonary arterial hypertension (PAH), or scleroderma renal crisis (SRC), positivity for anti-Scl-70 antibodies, delayed diagnosis, male sex, and older age at onset all independently predict worse outcomes and higher mortality risk.^[93]^[94] Organ-specific complications, such as those affecting the lungs or heart, further drive reduced survival when present.^[25] Quality of life in SSc is significantly impaired due to progressive disability, with elevated Health Assessment Questionnaire (HAQ) scores reflecting moderate to severe functional limitations (mean HAQ around 0.99).^[95] Remission is rare, though disease stabilization is achievable in many patients through timely intervention, mitigating further decline in daily activities. Progression is monitored using serial assessments, including the modified Rodnan skin score (mRSS) to evaluate skin involvement, pulmonary function tests (PFTs) for lung capacity, and the 6-minute walk test to detect early PAH or cardiopulmonary limitations.^[96] Historically, mortality from SRC has declined dramatically to less than 5% with the advent of angiotensin-converting enzyme inhibitors (ACEIs), shifting the primary causes of death toward pulmonary complications like ILD and PAH.^[25]

Epidemiology

Scleroderma, also known as systemic sclerosis (SSc), is a rare autoimmune disease with varying incidence and prevalence across populations. Globally, the pooled incidence is estimated at 1.4 cases per 100,000 person-years (95% CI 1.1–1.9), while the prevalence stands at 17.6 per 100,000 individuals (95% CI 15.1–20.5). In North America and Europe, incidence rates are higher, ranging from 1.6 to 2.0 per 100,000 person-years, with prevalence reaching 25.9 per 100,000 in North America and 14.8 per 100,000 in Europe. In contrast, Asia reports lower figures, with an incidence of 0.9 per 100,000 person-years and prevalence of 6.8 per 100,000. These differences highlight regional variations, potentially influenced by genetic, environmental, and diagnostic factors. Recent regional studies, such as in Quebec, Canada (as of 2019 data analyzed in 2024), report higher incidence rates (4.14 per 100,000 person-years) and increasing trends, potentially due to improved detection.^[97]^[98] The disease predominantly affects women, who account for 75–90% of cases, with a female-to-male ratio of approximately 4–10:1; prevalence is 28.0 per 100,000 in women compared to 6.0 per 100,000 in men. Onset typically occurs between ages 40 and 60 years, though it can manifest earlier or later. Juvenile systemic sclerosis, defined as onset before age 18, represents less than 10% of all cases, with incidence rates of 0.13–0.26 per 100,000 children annually in the United States. Ethnic disparities are notable, with higher prevalence among certain groups; for instance, full-blooded Choctaw Native Americans in Oklahoma exhibit a prevalence of 469 per 100,000—approximately 18 times the general North American rate of 25.9 per 100,000—linked to specific HLA haplotypes. African Americans also show elevated incidence compared to European Americans, particularly among women (2.25 vs. 1.28 per 100,000 person-years).^[98]^[99]^[40]^[100] Epidemiological trends indicate stable incidence over time, though recent studies suggest possible increases due to improved awareness and diagnostics, potentially underdiagnosing milder or localized forms in the past. Environmental factors, such as occupational exposure to silica in industrial areas, are associated with higher rates, with evidence of geographic clustering in regions with heavy manufacturing or mining activities. As a rare disease, SSc carries orphan drug designation in many countries, underscoring its low prevalence and high unmet needs. International registries like the European Scleroderma Trials and Research (EUSTAR) group, encompassing over 200 centers and more than 14,000 patients, facilitate ongoing data collection to track global burden and variations.^[98]^[38]^[101]^[102]

Special Populations and Advances

Pregnancy

Pregnancy in women with scleroderma, also known as systemic sclerosis (SSc), requires careful consideration due to potential interactions between the disease and gestational physiology, particularly involving vascular and fibrotic complications that can affect both maternal and fetal health. While fertility is generally unaffected, pregnancies are classified as high-risk, necessitating preconception planning and specialized monitoring to mitigate adverse outcomes. Localized scleroderma (morphea) poses lower risks compared to systemic forms, with most cases showing disease stability and no direct adverse pregnancy effects reported in small series.^[103] Maternal risks include rare but severe events such as scleroderma renal crisis (SRC), occurring in approximately 2% of pregnancies and peaking between 16 and 28 weeks' gestation, and pulmonary arterial hypertension (PAH) flares, which carry a maternal mortality rate of 17% to 33% and are considered a contraindication to pregnancy. Fetal risks are more common, encompassing preterm birth in 11% to 40% of cases (versus 11% in the general population), intrauterine growth restriction (IUGR) with a sixfold increased likelihood, and low birth weight or small-for-gestational-age infants in 15% to 21% of pregnancies. Additional concerns include a slightly elevated miscarriage rate of 12% to 15% in the first trimester and preeclampsia in about 12% of cases. These risks are heightened in early diffuse cutaneous SSc (dcSSc), where disease activity within the first five years correlates with worse outcomes.^[104]^[105]^[106] Optimal timing involves achieving disease stability for at least two years preconception, with pregnancy strongly discouraged in active early dcSSc due to elevated complication rates. Limited cutaneous SSc (lcSSc) carries lower risks, allowing safer planning after organ function optimization. Management entails a multidisciplinary approach involving rheumatologists, obstetricians, and maternal-fetal medicine specialists, with preconception counseling to assess organ involvement and adjust therapies. Safe medications include low-dose aspirin for preeclampsia prevention, hydroxychloroquine, azathioprine, low-dose corticosteroids (under 15 mg/day prednisone equivalent), and intravenous immunoglobulins; cyclophosphamide and mycophenolate mofetil must be discontinued preconception due to teratogenicity. Throughout pregnancy, serial monitoring of blood pressure, renal function, cardiac status, and fetal growth via ultrasound is essential, with aggressive hypertension control and folic acid supplementation recommended to reduce preterm birth risk. Delivery planning favors vaginal routes when possible, with regional anesthesia preferred over general in PAH cases, and postpartum hospitalization extended to 72 hours to 4 weeks for vigilance.^[104]^[105]^[107] Postpartum, disease exacerbation occurs in 20% to 30% of cases, including potential SRC or PAH progression, warranting close follow-up for 3 to 6 months. Breastfeeding is generally compatible but requires avoiding certain immunosuppressants like mycophenolate; safe options include hydroxychloroquine and low-dose corticosteroids. With appropriate planning and management, live birth rates reach 70% to 85%, comparable to the general population (84%), and congenital anomalies do not exceed those in other autoimmune diseases. No increased neonatal mortality is observed beyond general preterm risks.^[104]^[106]^[105]

Recent Research and Future Directions

Recent advancements in scleroderma research have focused on innovative clinical trial designs to accelerate the evaluation of antifibrotic therapies. The CONQUEST platform, launched in 2023 by the Scleroderma Research Foundation, represents a multicenter, adaptive trial framework specifically for systemic sclerosis-associated interstitial lung disease (SSc-ILD), enabling efficient testing of multiple investigational antifibrotics against placebo by assessing changes in lung function and skin scores.^[108]^[109] Promising results from phase 3 trials of biologics targeting immune pathways have emerged in 2025. The DAISY trial is evaluating subcutaneous anifrolumab, an anti-interferon therapy, in adults with systemic sclerosis to assess its efficacy and safety for skin and pulmonary manifestations.^[110]^[111] In immunotherapy, early-phase trials of CAR-T cell therapies targeting CD19 on B-cells have shown reductions in autoantibodies and preliminary improvements in skin fibrosis among small cohorts of patients in 2025, though larger studies are needed to confirm efficacy and safety.^[112] The RECITAL trial further supports rituximab's role in SSc-ILD, where it provided comparable benefits to cyclophosphamide in preserving forced vital capacity, with a favorable safety profile for long-term use.^[112] Basic research has advanced through sophisticated modeling and genomic techniques to dissect fibrotic mechanisms. In 2025, 3D organoid models derived from patient-induced pluripotent stem cells have been refined to recapitulate skin and lung fibrosis, facilitating high-throughput drug screening and revealing novel antifibrotic targets.^[113]^[114] Single-cell RNA sequencing studies have uncovered fibroblast heterogeneity in scleroderma, identifying pro-inflammatory subsets with upregulated TGF-β signaling that drive early disease progression, as presented at EULAR 2025.^[115]^[116] Efforts to identify biomarkers for early detection and risk stratification have leveraged multi-omics approaches. Downregulated circulating microRNA profiles, such as miR-29 and miR-150, have been validated as indicators of fibrotic progression and organ involvement in systemic sclerosis, with their decreased levels enabling personalized monitoring through integrated genomic and proteomic analyses.^[117]^[118]^[119]^[120] Looking ahead, gene therapy strategies inhibiting TGF-β pathways, including CRISPR-based editing, hold promise for reversing established fibrosis, with preclinical models showing sustained antifibrotic effects.^[121] Personalized medicine is advancing via AI algorithms that predict disease subtype trajectories and PAH risk from clinical and imaging data, potentially optimizing therapy selection.^[122] EULAR 2025 guidelines emphasized combination regimens for ILD and pulmonary arterial hypertension, integrating biologics with antifibrotics to address multi-organ involvement.^[123] Collaborative networks, such as the Scleroderma Research Foundation, have been instrumental in funding these initiatives and fostering interdisciplinary efforts to bridge gaps in biologics and disease modeling.^[124]^[125]

References

[1]
Scleroderma - Symptoms and causes - Mayo Clinic
Jun 15, 2024 · This group of rare diseases involves the hardening and tightening of the skin and connective tissues. Some forms can affect internal organs.
[2]
Scleroderma
### Summary of Scleroderma
[3]
Scleroderma - American College of Rheumatology
Scleroderma is a rare, chronic autoimmune disease that affects skin and internal organs. Scleroderma results from an overactive immune system causing ...
[4]
Systemic Sclerosis (Scleroderma) - StatPearls - NCBI Bookshelf - NIH
Systemic sclerosis, also known as scleroderma, is a rare connective tissue disorder with an unknown and complex pathogenesis. Scleroderma can be divided ...
[5]
Scleroderma: Symptoms, Causes & Treatment Options
Scleroderma is a rare condition that thickens your skin and tissue throughout your body. It can cause severe complications if it affects your organs.
[6]
The Pathogenesis of Systemic Sclerosis: The Origin of Fibrosis and ...
Whilst we know that SSc affects multiple organs via vasculopathy, inflammation, and fibrosis, its exact pathophysiology remains elusive.
[7]
What is Scleroderma?
Scleroderma is an autoimmune, rheumatic, and chronic disease that affects the body by hardening connective tissue.
[8]
Systemic sclerosis - DermNet
The general term 'scleroderma' is often used for both morphoea (localised scleroderma) and systemic sclerosis (systemic scleroderma). Distinguishing these two ...
[9]
Systemic Sclerosis (Scleroderma): Pictures, Symptoms, Causes
Dec 13, 2024 · What's the difference between scleroderma and systemic sclerosis? Scleroderma is seen only on the skin. However, when the fibrosis involves ...Missing: distinction | Show results with:distinction
[10]
Systemic Scleroderma—Definition, Clinical Picture and Laboratory ...
In 1836, a Milanese doctor, Giovambattista Fantonetti, first introduced the word 'scleroderma' into medical terminology [5]. Describing his patient's skin ...
[11]
Scleroderma: Practice Essentials, Background, Pathophysiology
Activated inflammatory and immune cells secrete cytokines, chemokines, and growth factors, which cause fibroblast activation, differentiation of endothelial and ...
[12]
Systemic Scleroderma - Symptoms, Causes, Treatment | NORD
Systemic sclerosis is a rare autoimmune disease that affects between 38 and 341 individuals per million worldwide (prevalence) and develops in 8 to 56 ...
[13]
Localized and systemic scleroderma - PubMed
Localized scleroderma is a cutaneous limited fibrosis that manifests as plaque morphea, generalized morphea, linear scleroderma, and deep morphea.
[14]
Systemic Sclerosis/Scleroderma: A Treatable Multisystem Disease
Oct 15, 2008 · Patients with systemic sclerosis can be classified into two distinct clinical subsets with different patterns of skin and internal organ ...
[15]
Systemic Sclerosis Types - Rare Disease Advisor
Apr 24, 2023 · A third, rare type of SSc (less than 5% of cases) is called systemic sclerosis sine scleroderma. One or more internal organs are affected ...
[16]
Pediatric Scleroderma –Systemic and Localized Forms - PMC
Pediatric scleroderma includes two major groups of clinical entities, systemic sclerosis (SSc) and localized scleroderma (LS).
[17]
Scleroderma overlap syndromes - PubMed
The most common scleroderma overlap syndromes are mixed connective tissue disease (MCTD), scleromyositis and synthetase syndrome.
[18]
Overlap syndromes - Symptoms, diagnosis and treatment
Nov 14, 2023 · MCTD is a distinct clinical entity characterized by overlapping features of systemic lupus erythematosus, scleroderma, myositis, and rheumatoid ...
[19]
Early diagnosis of progressive systemic sclerosis (scleroderma ... - NIH
As a result, skin, usually of the hands and feet, becomes stiff, tight and shiny. Most patients are adults and women are affected three times more often than ...
[20]
Scleroderma - Selected Immune Disorders and Disability - NCBI - NIH
Hyper- and hypo-pigmentation may develop, often with a salt-and-pepper appearance of the skin, which can be cosmetically and socially distressing.Clinical Features · Skin/cutaneous... · Juvenile SclerodermaMissing: hyperpigmentation | Show results with:hyperpigmentation
[21]
Raynaud's phenomenon - PMC - PubMed Central
RP occurs in the vast majority (>95%) of patients with systemic sclerosis and is often the earliest symptom of the disease.
[22]
Tendon friction rubs in early diffuse systemic sclerosis - NIH
Forty-nine of 134 patients (37%) had TFR at baseline. The most common sites with TFR were hands (20%) then ankles (18%), wrists (14%), knees (12%), elbows (7.6 ...
[23]
Prevalence and Clinical Implications of Scleroderma-Specific ... - NIH
Various features have been observed in patients suffering from dry mouth and dry eyes, ranging from non-specific symptoms and signs such as fatigue and ...
[24]
Update on morbidity and mortality in systemic sclerosis–related ...
Of the SSc-related deaths, 35% were attributed to ILD, 26% to pulmonary arterial hypertension (PAH), and 26% to cardiac causes (mainly heart failure and ...
[25]
Lung Involvement in Systemic Sclerosis - PMC - NIH
Lung involvement is a frequent complication and a leading cause of morbidity and mortality in this syndrome. Two major pulmonary syndromes are associated with ...
[26]
Scleroderma and Primary Myocardial Disease - StatPearls - NCBI
Aug 8, 2023 · Cardiac involvement in SSc is associated with increased mortality. Several complications can occur with myocardial disease, including heart ...
[27]
Scleroderma and Renal Crisis - StatPearls - NCBI - NIH
Most cases of scleroderma renal crisis occur in patients with diffuse scleroderma (10% to 25%) as compared to only 1% to 2% of patients with limited disease.Etiology · Epidemiology · Treatment / Management · Differential Diagnosis
[28]
Kidney disease in systemic sclerosis (scleroderma), including ...
Oct 14, 2024 · Scleroderma renal crisis (SRC) occurs in 5 to 20 percent of patients with diffuse cutaneous SSc and in 1 to 2 percent of patients with limited ...
[29]
Gastrointestinal manifestations of systemic sclerosis (scleroderma)
Jan 16, 2025 · Pathophysiology · Small intestinal bacterial overgrowth · Hypomotility and intestinal pseudo-obstruction · Malnutrition · Other.
[30]
Gastrointestinal Manifestations of Systemic Sclerosis - PMC
In addition, patients with cardiac, pulmonary, renal, and skin involvement tend to have more GI symptoms including diarrhea, constipation and a decreased gastro ...
[31]
Management of Calcinosis Associated with Systemic Sclerosis
Feb 2, 2016 · Calcinosis is a common and debilitating manifestation of systemic sclerosis (SSc). It most commonly involves the hands, particularly the fingers.Missing: malignancy | Show results with:malignancy
[32]
Systemic Sclerosis and Malignancy: A Review of Current Data - PMC
Jul 30, 2016 · Systemic sclerosis (SSc) is associated with increased risk of malignancy. The organ systems most commonly affected are the lungs, the breasts and the ...
[33]
Associations with digital ulcers in a large cohort of systemic sclerosis ...
Aug 25, 2010 · Digital ulcers are a common complication of systemic sclerosis (SSc; scleroderma). Approximately half of SSc patients have had a digital ulcer ...
[34]
Systemic scleroderma: MedlinePlus Genetics
Jul 1, 2020 · In diffuse cutaneous systemic scleroderma, the condition worsens quickly and organ damage occurs earlier than in other types of the condition.<|control11|><|separator|>
[35]
The Genetics of Systemic Sclerosis - PMC - PubMed Central - NIH
While the pathogenesis of SSc is not completely understood, familial studies and genetic studies suggest that SSc is a complex polygenic disease.
[36]
Epigenetics of scleroderma: Integrating genetic, ethnic, age ... - NIH
This review starts by summarizing the changes in DNA methylation, histone modification, and non-coding RNAs associated with systemic sclerosis.
[37]
Risk factors for the development of systemic sclerosis: a systematic ...
Middle age, female sex, positive family history and exposure to silica are risk factors for scleroderma. ... factors are a major cause of SSc [4, 12, 13].
[38]
Systemic sclerosis and infections - PubMed
Numerous infectious agents (bacterial and viral) have been proposed as possible triggering factors (Parvovirus B19, Cytomegalovirus, Epstein-Barr virus, ...
[39]
Increased prevalence of systemic sclerosis in a Native American ...
The overall prevalence of SSc in Oklahoma Choctaws (66/100,000) also was significantly higher than that in other Native Americans in Oklahoma (9.5/100,000) (P = ...Missing: incidence | Show results with:incidence
[40]
Pathophysiology of systemic sclerosis (scleroderma) - Rosendahl
Mar 2, 2022 · Its pathophysiology is complex and involves an early endothelial damage, an inflammatory infiltrate and a resulting fibrotic reaction.<|control11|><|separator|>
[41]
A review of recent studies on the pathogenesis of Systemic Sclerosis
Systemic Sclerosis (SSc) is a systemic autoimmune disease characterized by a severe fibrotic process affecting the skin and multiple internal organs.
[42]
Pathophysiology in Systemic Sclerosis: Current Insights and Future ...
The pathophysiology involves an interplay of chronic inflammation, impaired vascular function, and excessive extracellular matrix deposition, leading to ...
[43]
2013 Classification Criteria for Systemic Sclerosis: An American ...
Oct 3, 2013 · The ACR/EULAR classification criteria for SSc perform better than 1980 ACR preliminary criteria in terms of both sensitivity and specificity.
[44]
Standardization of the modified Rodnan skin score for use in clinical ...
May 15, 2017 · The modified Rodnan skin score (mRSS) is a measure of skin thickness and is used as a primary or secondary outcome measure in clinical trials of systemic ...
[45]
Systemic Sclerosis-Specific Antibodies: Novel and Classical ...
ANA are present in more than 90% of SSc, but ANA negativity does not exclude SSc diagnosis: a little rate of SSc ANA negative exists and shows a distinct ...
[46]
Autoantibodies in the disease criteria for systemic sclerosis
The ACR/EULAR classification criteria for systemic sclerosis (SSc) entail three autoantibodies: anti-centromere antibodies (ACA), anti-topoisomerase I ...Autoantibodies In The... · 3. Scientific Background For... · 4. Influence Of Different...
[47]
Association of C‐reactive protein with high disease activity in ...
May 3, 2012 · CRP level is elevated in one-quarter of SSc patients, especially early disease. It is correlated with disease activity, severity, poor pulmonary function, and ...
[48]
Nailfold capillaroscopy in systemic sclerosis – state of the art - NIH
Capillaroscopy is a unique method for morphological evaluation of the nailfold capillaries that plays a crucial role for early diagnosis of systemic sclerosis.
[49]
High resolution computed tomography in systemic sclerosis
Oct 21, 2024 · High-resolution computed tomography (HRCT) of the chest is recognized as the most accurate imaging modality for baseline and follow-up evaluation of SSc-ILD.
[50]
Echocardiography and pulmonary function as screening tests for ...
Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology (Oxford). 2004 Apr;43(4): ...
[51]
Scleroderma Workup: Approach Considerations, Laboratory Studies ...
Mar 1, 2023 · Skin biopsy showing severe fibrosis. The fibrosis reflects a widening of collagen bundles in concert with an increase in the number of collagen ...
[52]
Predicting the Progression of Very Early Systemic Sclerosis
Sep 15, 2022 · For example, when a given patient develops their first non-Raynaud symptom of SSc (eg, puffy hands) within 1–2 years of the onset of Raynaud ...
[53]
The differential diagnosis of systemic sclerosis - PubMed
Purpose of review: The new American College of Rheumatology/European League Against Rheumatism classification criteria will enable earlier diagnosis and, ...
[54]
Systemic Sclerosis Differential Diagnosis - Rare Disease Advisor
Apr 19, 2023 · The differential diagnosis of SS considers skin manifestations, vascular features, and complications in internal organs.
[55]
Scleroderma Differential Diagnoses - Medscape Reference
Mar 1, 2023 · Nephrogenic Systemic Fibrosis · Eosinophilic Fasciitis · Eosinophilia-Myalgia Syndrome · Graft Versus Host Disease · Reflex Sympathetic Dystrophy.
[56]
Scleroderma Mimickers - PMC - NIH
Scleroderma is a rare autoimmune disorder, with a national annual incidence of 20 cases per million in the United States, and an estimated prevalence of 150 ...Scleroderma Mimickers · Scleredema · Scleromyxedema
[57]
Differential diagnosis of scleroderma and pseudoscleroderma
For differential diagnosis, the presence of Raynaud phenomenon, antinuclear antibodies and the distribution of sclerosis play essential roles.
[58]
Scleroderma Mimickers - ResearchGate
Nailfold capillaroscopy can aid in differentiating sclerodermoid skin diseases that mimic SSc (e.g., pansclerotic morphea, eosinophilic fasciitis) from true SSc ...
[59]
EULAR recommendations for the treatment of systemic sclerosis
Oct 17, 2024 · High-intensity immunosuppression (usually including cyclophosphamide) followed by autologous haematopoietic stem cell transplantation (HSCT) may ...
[60]
2024 British Society for Rheumatology guideline for management of ...
Sep 11, 2024 · MMF is recommended as first-line treatment. Rituximab and/or cyclophosphamide by i.v. infusion may be used as an alternative (1B, 97%). Consider ...
[61]
Expert consensus on the management of systemic sclerosis ...
Jan 9, 2023 · Panelists considered MMF as first-line therapy for patients with SSc-ILD at a target dose of 2000–3000 mg daily. Initial nintedanib therapy, at ...
[62]
Comparative Efficacy of Immunosuppressive Therapies in the ...
Mar 10, 2025 · Prior studies have demonstrated cyclophosphamide to be superior to placebo for the treatment of scleroderma-associated ILD in a trial that ...
[63]
Immunosuppression use in early systemic sclerosis may be ...
Mar 29, 2021 · Methotrexate is being more frequently used, and mycophenolate mofetil has gained favour over cyclophosphamide. Autoantibody status was the most ...
[64]
Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease
In conclusion, the results of the SENSCIS trial showed that nintedanib has a beneficial effect by reducing the rate of decline in FVC in patients with ILD ...
[65]
Treating Raynaud phenomenon: Beyond staying warm
Oct 1, 2017 · Dihydropyridine calcium channel blockers such as nifedipine and amlodipine are commonly used. Both drugs are acceptable options, though some ...
[66]
Addition of sildenafil to bosentan monotherapy in pulmonary arterial ...
Addition of sildenafil after bosentan monotherapy failure improved New York Heart Association class and 6-min walk distance in idiopathic pulmonary arterial ...
[67]
Captopril in the Treatment of Scleroderma Renal Crisis
These data suggest that captopril is beneficial in the treatment of scleroderma renal crisis. (Arch Intern Med 1984;144:733-735).
[68]
Autologous Hematopoietic Stem Cell Transplantation vs Intravenous ...
Jun 25, 2014 · It is still unclear whether HSCT prolongs survival in systemic sclerosis. We therefore conducted a randomized clinical trial called ASTIS ( ...
[69]
Tocilizumab in Patients with Systemic Sclerosis–associated ...
Jan 21, 2023 · Tocilizumab use in patients with SSc-ILD is associated with less disease progression and a better toxicity profile than placebo.Methods · Results · Discussion · Conclusions
[70]
Scleroderma - Diagnosis and treatment - Mayo Clinic
Jun 15, 2024 · This group of rare diseases involves the hardening and tightening of the skin and connective tissues. Some forms can affect internal organs.
[71]
Scleroderma Treatment & Management - Medscape Reference
Mar 1, 2023 · Instruct the patient to perform continuous physical and occupational therapy to maintain joint range of motion and to minimize or delay joint ...
[72]
[PDF] Stretching Exercises for the Hand and Face
Stretching can help you improve flexibility for facial expressions and oral care. Page 3 of 4. National Scleroderma Foundation Medical Report: Stretching ...
[73]
Rehabilitation Interventions in Systemic Sclerosis: A Systematic ...
To systematically review evidence of rehabilitation interventions for improving outcomes in systemic sclerosis (SSc) and to evaluate evidence quality.
[74]
Occupational therapy for scleroderma
Occupational therapy for scleroderma. An Occupational Therapist (OT) can support and guide you to manage your symptoms to help you lead a fulfilling life.
[75]
Occupational Therapy and Scleroderma (Systemic Sclerosis)
Jun 3, 2014 · To discuss occupational therapy intervention to increase joint motion, reduce pain and manage daily tasks, fatigue and Raynaud's phenomenon.Missing: guidelines | Show results with:guidelines
[76]
Review of local wound management for scleroderma-associated ...
Nov 17, 2017 · Digital ulcers (DU) are a common clinical problem in systemic sclerosis (SSc); however, there is no standardization of local wound care ...
[77]
Optimal management of digital ulcers in systemic sclerosis - PMC
Jun 15, 2015 · Local wound care measures include the application of topical hydrocolloid and occlusive dressings to protect the affected skin and prevent ...Pharmacological Intervention · Local And Surgical... · Local Wound Care
[78]
Digital ulcers in scleroderma | Royal Free London
Apr 14, 2025 · Contractures; Trauma (e.g. knocking fingers on objects); Calcinosis ... It is one of scleroderma complications. However, there are things ...
[79]
Skin Ulcers & Scleroderma: Complications and Treatments
Treatments for Scleroderma Skin Ulcers: Basic wound care and over-the-counter (OTC) medications may help with healing and pain management. Medications for ...
[80]
Management of gastrointestinal involvement in scleroderma - NIH
SSc patients with GI involvement are at risk for malnutrition; various causes exist including malabsorption from SIBO, dysmotility in various segments of the ...
[81]
[PDF] Nutritional Implications of GI-Related Scleroderma
This problem, known as chronic intestinal pseudo-obstruction. (CIPO), leads to severe constipation. There is smooth muscle atrophy, predominantly of the ...
[82]
Nutritional Implications of GI-Related Scleroderma - Practical Gastro
Dietary modification is helpful in mild cases of intestinal involvement in SSc. A balanced healthy diet should be continued as long as possible. Intake of fats ...
[83]
Oral, enteral and parenteral nutritional therapies in scleroderma
These may result in GI dysmotility, potentially affecting any part of the GI ... nutritional support on nutritional and clinical outcomes in scleroderma patients.
[84]
Treatments & Medications - National Scleroderma Foundation
Calcium channel blockers: Nifedipine or amlodipine. Possible side effects: Because calcium channel blockers open your blood vessels, your blood pressure drops.
[85]
Pain and fatigue in systemic sclerosis: Practical strategies for non ...
Sep 23, 2025 · Non-pharmacological treatments, including exercise therapy, cognitive behavioural strategies, patient education and rehabilitation programmes, ...<|separator|>
[86]
Multidisciplinary health care team in the management of SSc | JMDH
Apr 20, 2022 · Multi-disciplinary teams (MDT) are composed of rheumatologists and other specialists and comprise both physicians and other health professionals ...
[87]
Scleroderma Treatment | Johns Hopkins Medicine
Treating Scleroderma · Getting pain relief through nonsteroidal, anti-inflammatory medications or corticosteroids · Easing skin itchiness with skin lotions and ...Missing: guidelines | Show results with:guidelines
[88]
Lung transplantation in patients with scleroderma - PubMed
Lung transplantation represents a viable therapeutic option to consider for patients with end-stage lung disease due to SSc who have limited extrapulmonary ...
[89]
Lung Transplantation for Scleroderma-related Lung Disease - PMC
Nov 8, 2016 · Lung transplantation for scleroderma-related lung disease is controversial due to extra-pulmonary organ involvement that may threaten allograft and patient ...Introduction · Table 1 · Table 2<|control11|><|separator|>
[90]
[PDF] Lung Transplant in Patients with Connective Tissue Diseases
27 Other approaches that have been used in patients diagnosed with CTDs. (mainly SSc) and Raynaud phenomenon include sympathectomy at the time of transplant ( ...
[91]
a nationwide population-based matched cohort study | Rheumatology
The 5-year survival was 79.8% and the 10-year survival was 67.7% among patients with SSc vs 92.9% and 84.8%, respectively, for the comparators.<|control11|><|separator|>
[92]
Survival and prognostic factors from a multicentre large cohort of ...
Apr 3, 2023 · Male gender, diffuse cutaneous involvement, comorbidities and PAH with or without ILD represent the main poor prognostic factors.
[93]
Survival, Mortality, Causes of Death and Risk Factors of Poor Outcome
Risk factor predictors of poor outcomes are an elder age at diagnosis, the male gender, diffuse subset, visceral involvement and non-Raynaud's phenomenon onset.
[94]
Health-related quality of life in systemic sclerosis compared with ...
Feb 15, 2019 · SSc patients reported a mean HAQ-DI score of 0.99 and a mean combined SHAQ score of 0.87. Among SSc patients, 79 (65.8%) had dcSSc and the ...Study Patients · Assessment Of Hrqol · Hrqol In Patients With...
[95]
Health-related quality of life in patients with systemic sclerosis - NIH
Jan 5, 2021 · The HAQ comprises 20 items divided into eight domains, with a final composite score ranging from 0 (no disability) to 3 (maximal disability).
[96]
Systemic Sclerosis–Associated Interstitial Lung Disease: How to ...
Jul 27, 2021 · Oxygen therapy should be considered in cases of hypoxemia (SpO2 <88%). The 6-minute walk test is useful to evaluate cardiopulmonary exercise ...
[97]
Incidence and prevalence of systemic sclerosis globally
SSc has throughout the literature been described as a rare disease. Reports ... Prevalence of scleroderma spectrum disorders in the general population of South ...
[98]
Systemic Sclerosis Epidemiology - Rare Disease Advisor
Apr 27, 2023 · The estimated prevalence of SSc ranged from 7.2 to 33.9 per 100,000 people in Europe and from 13.5 to 44.3 per every 100,000 people in North ...
[99]
Incidence and prevalence of juvenile SSc in the United States - NIH
Oct 16, 2025 · Roughly 2%–10% of systemic sclerosis cases develop during juvenile years (under 18 years of age); however, there are limited data on the ...
[100]
Systemic sclerosis - ScienceDirect.com
Systemic sclerosis is uncommon and is designated an orphan disease with a high unmet medical need. 3, 4, 5 Diagnosis can often be delayed, which adds to the ...
[101]
EUSTAR – European Scleroderma Trials and Research Group
Jan 5, 2023 · The European Scleroderma Trials and Research group (EUSTAR) is an international research network consisting of over 200 scleroderma centers. Led ...EUSTAR fellowship · EUSTAR Bursary · EUSTAR SSc Live Course · Database
[102]
Morphea disease activity during pregnancy: A case series - PubMed
Sep 12, 2022 · In this small series, most patients maintained stability of their morphea and there were no adverse pregnancy outcomes directly related to morphea.Missing: risks | Show results with:risks
[103]
Systemic sclerosis in pregnancy - PMC - NIH
This review aims to describe the risks associated with systemic sclerosis and pregnancy ... guidelines on the diagnosis and management of scleroderma renal crisis ...
[104]
Special considerations in pregnant systemic sclerosis patients
Early during the pregnancy, a multidisciplinary team should be involved in the management of a SSc pregnancy. It includes a close follow-up with an obstetrician ...4. Impact Of Ssc On Women's... · 5. Effects Of Pregnancy On... · 6. Pregnancy Management
[105]
Systemic sclerosis and pregnancy outcomes: a retrospective study ...
Apr 27, 2022 · Pregnancy in systemic sclerosis (SSc) patients is no more an infrequent event as it used to be, but literature data on pregnancy outcomes in ...
[106]
Comprehensive Approach to Systemic Sclerosis Patients During ...
For the treatment of SS associated arthritis during pregnancy, painkillers such as paracetamol may be used, as well as low doses of corticosteroids (less than ...
[107]
NCT06195072 | Platform Clinical Study for Conquering Scleroderma
The goal of this clinical trial is to test efficacy of different investigational products (IPs) compared with placebo on the change from baseline to the end ...Missing: anifrolumab CAR-
[108]
Announcing CONQUEST, a Clinical Trial for SSc-ILD
Aug 1, 2023 · CONQUEST is designed to rapidly advance promising treatments for scleroderma and to identify those agents that should progress.Missing: anifrolumab CAR- T rituximab RECITAL
[109]
Determine effectiveness of Anifrolumab In SYstemic sclerosis (DAISY)
Evaluate anifrolumab's efficacy and safety against placebo in systemic sclerosis patients; join our trial to aid research on this debilitating disease.Missing: 2024 CONQUEST platform CAR- T rituximab
[110]
UCLA Diffuse Scleroderma Clinical Trials for 2025 — Los Angeles
Oct 22, 2025 · The purpose of this study is to evaluate the efficacy and safety of treatment with subcutaneous anifrolumab versus placebo in adult participants ...Missing: CAR- T rituximab RECITAL
[111]
New horizons in systemic sclerosis treatment: advances and ...
Jul 1, 2025 · This review provides an up-to-date synthesis of both current organ-based treatment strategies in major organ domains—skin, ILD, PAH, scleroderma ...
[112]
New 3D tissue model offers hope for scleroderma treatment
Jul 22, 2025 · "By pinpointing which genes are active in each individual cell, we can better understand what drives disease and help determine more quickly ...
[113]
Lab-Grown Skin Model Aids Drug Testing for Scleroderma
Jul 23, 2025 · Discover how lab-grown skin gives insight into fibrosis and could fast-track life-saving scleroderma treatments.
[114]
Fibroblast Subpopulations in Systemic Sclerosis - PubMed
Dec 24, 2023 · In this study, we integrated single-cell RNA-sequencing and bulk RNA-sequencing data as well as clinical information to study the role of individual fibroblast ...Missing: 2025 3D organoid
[115]
EULAR 2025: Single-Cell Study Reveals Pro-Inflammatory ... - EMJ
Jun 13, 2025 · A study presented at EULAR 2025 has revealed a strong pro-inflammatory gene signature in fibroblasts from patients with very early systemic sclerosis (veSSc).
[116]
MicroRNAs in Systemic Sclerosis: Involvement in Disease ... - NIH
Altered miRNA expression in circulation and disease-specific tissues could serve as biomarkers and potential therapeutic targets in SSc.
[117]
Update on biomarkers in systemic sclerosis: tools for diagnosis and ...
It has been shown that the elevated expression of pro-fibrotic miRNAs and reduced expression of antifibrotic miRNAs are important factors in the developments of ...Circulating Mirna · Biomarkers For Disease... · Interstitial Lung Disease
[118]
The fibrosis puzzle of systemic sclerosis-associated ILD and the ...
Aug 16, 2025 · Unlike cell therapy, gene editing could offer a more permanent modification of disease mechanisms. However, significant challenges remain, ...
[119]
Leveraging Artificial Intelligence for the Diagnosis of Systemic ...
Oct 17, 2025 · The integration of AI into screening algorithms could revolutionize SSc-PAH management by reducing diagnostic delays, optimizing referrals for ...
[120]
New horizons in systemic sclerosis treatment: advances and ...
Jul 1, 2025 · This review provides an up-to-date synthesis of both current organ-based treatment strategies in major organ domains—skin, ILD, PAH, scleroderma ...
[121]
SRF Research Program - Scleroderma Research Foundation
The SRF's research program actively seeks out and recruits experts from the fields of rheumatology, immunology, genetics, and fibrosis.Missing: networks biologics
[122]
Scleroderma Research Foundation | SRF | Research for a Cure
All of the SRF's funded research is focused on finding better treatments for scleroderma and ultimately a cure for scleroderma. Dive deeper into the details of ...Ways to Give · About Us · Contact the SRF · Our ResearchMissing: networks biologics models